KRYSTAL BIOTECH INC. - COMMON STOCK

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

03 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Upcoming Investor Conferences

05 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces $160 Million Private Placement Equity Financing

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

19 May 2023 13:57:02 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

08 May 2023 08:23:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

13 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

02 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

27 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

18 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

09 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

14 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

01 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

23 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

17 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

29 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

21 Sep 2022 16:30:00 By Nasdaq GlobeNewswire